Crunching the numbers for IDYA... Refresh in a moment for the full analysis.
IDEAYA Biosciences, Inc. (IDYA)
weak
$30.5
Updated: 2026-04-13
43
TradeApes Score
reduce
Financial Strength
50
Mixed
Operating Trend
30
Weak
Valuation
40
Weak
Capital Allocation
30
Weak
Risk
80
Strong
Key Findings
+
Low leverage — net debt/EBITDA below 1×
−
Excessive stock comp — SBC above 15% of revenue, wealth transfer to employees
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Add to Watchlist
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.